Challenges and Future Trends in Atopic Dermatitis

Abstract

Atopic dermatitis represents a complex and multidimensional interaction that represents potential fields of preventive and therapeutic management. In addition to the treatment armamentarium available for atopic dermatitis, novel drugs targeting significant molecular pathways in atopic dermatitis biologics and small molecules are also being developed given the condition’s complex pathophysiology. While most of the patients are expecting better efficacy and long-term control, the response to these drugs would still depend on numerous factors such as complex genotype, diverse environmental triggers and microbiome-derived signals, and, most importantly, dynamic immune responses. This review article highlights the challenges and the recently developed pharmacological agents in atopic dermatitis based on the molecular pathogenesis of this condition, creating a specific therapeutic approach toward a more personalized medicine.

Atopic dermatitis in early life and pain at 10 years of age: An exploratory study

“…In the near future, it would be advantageous to screen the pain complaints/discomfort routinely in appointments to improve the prevention measures and to diagnose and to treat flares earlier. The current evidence and advances for the potential treatment of atopic dermatitis have been studied by targeting specific interleukin (p.e IL1, IL33), common in both inflammatory pathways pain in atopic dermatitis [ 34 ]. Pharmacological treatment targeting these specific interleukines (p.e canakinumab) may be a potential treatment in atopic dermatitis especially associated with pain [ 34 ].…”

“…The current evidence and advances for the potential treatment of atopic dermatitis have been studied by targeting specific interleukin (p.e IL1, IL33), common in both inflammatory pathways pain in atopic dermatitis [ 34 ]. Pharmacological treatment targeting these specific interleukines (p.e canakinumab) may be a potential treatment in atopic dermatitis especially associated with pain [ 34 ]. Nevertheless, ours is an exploratory study and a lot remains to be clarified regarding the complex early life influences on chronic pain in the general population, as seen, e.g.…”

Yeast-Derived Nucleotides Enhance Fibroblast Migration and Proliferation and Provide Clinical Benefits in Atopic Dermatitis

“…Within the veterinary medicine field, dietary nucleotides also have many potential applications. In the particular case of CAD, novel therapies should focus on topical delivery, improving the skin barrier function and enhancing treatment compliance by the owners [ 20 , 34 , 43 , 44 , 45 , 46 ]. Therefore, solutions could arise from alternatives that help maintain the patient in remission or extend the length of the proactive phase of the disease.…”

“…Targeting the immune response has been suggested as an approach to developing new therapies for atopic dermatitis [ 34 ]. Since nucleotides modulate the immune response and have been shown to improve different parameters involved in the functioning of the immune system, using them in atopic dermatitis-like conditions could provide additional benefits.…”

Allergic Contact Dermatitis and Atopic Dermatitis: Highlights of the Overlap Syndrome

“…Іноді важко відрізнити AД, подразнюючий (іритантний) контактний дерматит (ІКД) і алергічний контактний дерматит, оскільки всі вони можуть проявлятись як екзематозний дерматит і можуть існувати одночасно. Порушення бар'єрної функції при AД сприяє розвитку як AКД, так і IКД, оскільки ці три стани мають спільні механізми [6,7]. Поширеність АКД є принаймні такою ж серед пацієнтів з АД, як і в загальній популяції; отже, пацієнтів із хронічним стійким дерматитом слід обстежити та розглянути можливість проведення патч-тестів.…”